Alpha Tau’s $196.5M Tolmar Pact Drives 22% Stock Surge
DRTS•Alpha Tau Medical secured a $20 million equity investment at $11.99 per share and $15 million for U.S. manufacturing from Tolmar, plus up to $161.5 million in milestones, totaling $196.5 million for exclusive U.S. rights to Alpha DaRT in prostate cancer with a bladder-cancer option. Shares jumped 22% on the deal.
1. Strategic Collaboration
Alpha Tau Medical signed an agreement with Tolmar granting exclusive U.S. commercialization rights for Alpha DaRT in prostate cancer, along with an option to expand into bladder cancer upon additional payments.
2. Financial Commitments
Tolmar will invest $20 million in equity at $11.99 per share and contribute $15 million toward expanding U.S. manufacturing capacity. Alpha Tau may receive up to $161.5 million in development, regulatory and commercial milestones, bringing total commitments to $196.5 million.
3. Development and Commercial Roles
Alpha Tau will lead clinical development and manufacture Alpha DaRT, selling doses to Tolmar at 60% of the onward net sales price. Tolmar will manage U.S. sales, marketing and distribution through its urology and oncology channels.
4. Market Reaction
Shares of Alpha Tau Medical surged 22% following the announcement, with retail sentiment turning bullish despite trading volume of about 0.6 million shares versus a one-million-share average.
